explore -WSS

explore

author：explore 2025-09-27 10:05:42 - browse：5783

prostate cancer cells — Prostate cancer cells seen under the microscope. NIH

Prostate cancer tends to be the tortoise of tumors, growing and spreading slowly. When cancerous cells escape the golf ball-sized prostate, they can lodge in various places throughout the body. New research shows that where these cells go can affect how long a man survives.

When prostate cancer spreads, or metastasizes, about three-quarters of the time it takes up residence in the bones. Less common locations are the lungs, liver, and lymph nodes.

An international team of researchers pooled information from nine clinical trials to estimate the average survival times for men with prostate cancer that had spread to four different tissues. Metastasis to the lymph nodes was linked to the longest survival; metastasis to the liver led to the shortest.

“This important study confirms that one size does not fit all when it comes to metastatic prostate cancer,” said Dr. Marc Garnick, a prostate cancer specialist at Beth Israel Deaconess Medical Center in Boston.

The new study, led by Susan Halabi, a professor of biostatistics at Duke University School of Medicine, suggests that prostate cancer that skips the bones and spreads to the liver and lungs may represent a different disease than prostate cancer that invades bones or lymph nodes. The results were published Monday in the Journal of Clinical Oncology.

Median survival for metastatic prostate cancer is affected by metastasis site. Mark Dubowski for Duke Health

“A better understanding of how metastatic prostate cancer behaves in different locations is letting us tailor diagnostic approaches and treatments that we hope will improve outcomes,” Garnick said.

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Biden's order seeks to regulate AI risk without stifling innovation

explore

WSS

Videos point to link between seizures and unexplained toddler deaths

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Burning questions for the 2024 JPM Healthcare Conference

Meta's Zuckerberg and Chan on track to put $50 billion into science

Maker of FluMist seeks to allow at

Feng Zhang CRISPR delivery startup lays off quarter of staff

focus

explore

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Feng Zhang, Grail founder join forces on new gene editing startup

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

JPM: CVS says Medicare Advantage patients are impacting profits

How one medical school became remarkably diverse

U.K. sequencing study surfaces new findings about tumor DNA

DIEP, the 'gold standard' of breast reconstruction, is under threat

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

State Dept. review finds Biden bears some blame for Afghanistan failures

Traditional Chinese medicine benefits explored in new JAMA study

focus

A single drug, study failures leave Anavex with nothing but cash

AdventHealth escalates lawsuit against insurance vendor Multiplan

Diversifying clinical trials isn't enough to close racial gaps: study

Testing for cancer recurrence creates a new limbo for patients

Eli Lilly to pay $200M for Beam’s stake in gene

Emergency medicine has repudiated 'excited delirium.' Now what?

explore

explore

Wikipedia

leisure time